# Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma

> **NCT02117258** · PHASE2 · COMPLETED · sponsor: **Zeria Pharmaceutical** · enrollment: 167 (actual)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Z-360
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02117258
- **Lead sponsor:** Zeria Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-07
- **Final completion:** 2017-03
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02117258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02117258, "Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02117258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*